Ahmed, Z., Fraser, W., Kerr, M. P., Kiernan, C., Emerson, E., Robertson, J., Felce, D., Allen, D., Baxter, H., & Thomas, J. (2000). Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry, 176, 42–46.
Barratt, M., Jorgensen, M., Deb, S., Limbu, B., Donley, M., Buchholtz, M., Smith, V., & Wilson, N. (2023). Staff perceptions following a training programme about reducing psychotropic medication use in adults with intellectual disability: The need for a realistic professional practice framework. Journal of Applied Research in Intellectual Disabilities, 36, 486–496. https://doi.org/10.1111/jar.13070
Bertelli, M. O., Azeem, M. W., Underwood, L., Scattoni, M. L., Persico, A. M., Ricciardello, A., Sappok, T., Bergmann, T., Keller, R., Bianco, A., Corti, S., Miselli, G., Lassi, S., Croce, L., Bradley, E., & Munir, K. (2022). Autism spectrum disorder. In M. O. Bertelli, S. Deb, K. Munir, A. Hassiotis, & L. Salvador-Carulla (Eds.), Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder (pp. 369–455). Springer Nature. https://doi.org/10.1007/978-3-319-95720-3_16
Branford, D. (1996). A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. Journal of Intellectual Disability Research, 40(4), 358–368.
Cervantes, P. E., Matson, J. L., Matheis, M., & Burns, C. O. (2017). Ethical considerations regarding treatment. In J. L. Matson (Ed.), Handbook of Treatments for Autism Spectrum Disorder, Autism and Child Psychopathology Series (pp. 41–58). Springer International Publishing AG. https://doi.org/10.1007/978-3-319-61738-1_3
Cooper, S.-A., McLean, G., Guthrie, B., McConnachie, A., Mercer, S., Sullivan, S., & Morrison, J. (2015). Multiple physical and mental health comorbidity in adults with intellectual disabilities: Population-based cross-sectional analysis. BMC Family Practice, 16, 110–121. https://doi.org/10.1186/s12875-015-0329-3
Article PubMed PubMed Central Google Scholar
Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., Whitaker, A., & Perrin, J. M. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130(suppl 2), s69–s76. https://doi.org/10.1542/peds.2012-0900D
de Kuijper, G. M., & Hoekstra, P. J. (2018). An open-label discontinuation trial of long-term, off-label antipsychotic medication in people with intellectual disability: Determinants of success and failure. The Journal of Clinical Pharmacology, 58(11), 1418–1426.
de Kuijper, G., Hoekstra, P., Visser, F., Scholte, F. A., Penning, C., & Evenhuis, H. (2010). Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: Prevalence and reasons for prescription. Journal of Intellectual Disability Research, 54(7), 659–667. https://doi.org/10.1111/j.1365-2788.2010.01275.x
de Kuijper, G., Mulder, H., Evenhuis, H., Scholte, F., Visser, F., & Hoekstra, P. J. (2013). Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics. Research in Developmental Disabilities, 34, 2799–2809. https://doi.org/10.1016/j.ridd.2013.05.016
de Kuijper, G., Evenhuis, H., Minderaa, R. B., & Hoekstra, P. J. (2014). Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. Journal of Intellectual Disability Research, 58(1), 71–83.
de Kuijper, G., de Haan, J., Deb, S., & Shankar, R. (2022). Withdrawing antipsychotics for challenging behaviours in adults with intellectual disabilities: Experiences and views of the experts by experience. International Journal of Environmental Research and Public Health, 19, 15637. https://doi.org/10.3390/ijerph192315637
Article PubMed PubMed Central Google Scholar
Deb, S., & Limbu, B. (2022). Support staff liaising effectively with family caregivers: Findings from a co-design event and recommendation for a staff training resource. Frontiers in Psychiatry, 13, 977442. https://doi.org/10.3389/fpsyt.2022.977442
Article PubMed PubMed Central Google Scholar
Deb, S., Clarke, D., & Unwin, G. (Eds.). (2006). Using medication to manage behaviour problems among adults with a learning disability: Quick reference guide (QRG). University of Birmingham ENCAP The Royal College of Psychiatrists www.ld-medication.bham.ac.uk
Deb, S., Kwok, H., Bertelli, M., Salvador-Carulla, L., Bradley, E., Torr, J., & Barnhill, J. (2009). International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry, 8(3), 181–186. https://doi.org/10.1002/j.2051-5545.2009.tb00248.x
Article PubMed PubMed Central Google Scholar
Deb, S., Unwin, G., & Deb, T. (2015). Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. Journal of Intellectual Disability Research, 59(1), 11–25. https://doi.org/10.1111/jir.12119
Deb, S., Limbu, B., Unwin, G., Woodcock, L., Cooper, V., & Fullerton, M. (2021). Short-term psycho-education for caregivers to reduce overmedication of people with intellectual disabilities (SPECTROM): Development and field testing. International Journal of Environmental Research and Public Health, 18, 13161. https://doi.org/10.3390/ijerph182413161
Deb, S., Perera, B., Krysta, K., Ozer, M., Bertelli, M., Novell, R., Wieland, J., & Sappok, T. (2022a). The European guideline on the assessment and diagnosis of psychiatric disorders in adults with intellectual disabilities. European Journal of Psychiatry, 36, 11–25. https://doi.org/10.1016/j.ejpsy.2021.10.002
Deb, S., Bertelli, M. O., & Rossi, M. (2022b). Psychopharmacology. In M. O. Bertelli, S. Deb, K. Munir, A. Hassiotis, & L. Salvador-Carulla (Eds.), Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder (pp. 247–279). Springer Nature, (chapter 11). https://doi.org/10.1007/978-3-319-95720-3_11
Deb, S., Unwin, G. L., Cooper, S.-A., & Rojahn, J. (2022c). Problem behaviours. In M. O. Bertelli, S. Deb, K. Munir, A. Hassiotis, & L. Salvador-Carulla (Eds.), Textbook of Psychiatry for Intellectual Disability and Autism Spectrum Disorder (pp. 145–186). Springer Nature, (chapter 7). https://doi.org/10.1007/978-3-319-95720-3_7
Deb, S., Roy, M., & Limbu, B. (2023a). Psychopharmacological treatments for psychopathology in people with intellectual disabilities and/or autism spectrum disorder. British Journal of Psychiatry Advances, 29, 322–333. https://doi.org/10.1192/bja.2022.61
Deb, S., Roy, M., Limbu, B., Akrout Brizard, B., Murugan, M., Roy, A., & Santambrogio, J. (2023b). Randomised controlled trials of antipsychotics for people with autism spectrum disorder: A systematic review and a meta-analysis. Psychological Medicine (Early View). https://doi.org/10.1017/S003329172300212X
Department of Constitutional Affairs. (2005). Mental Capacity Act 2005. The Stationery Office.
Elford, H., Beail, N., & Clarke, Z. (2010). A very fine line’: Parents’ experiences of using restraint with their adult son/daughter with intellectual disabilities. Journal of Applied Research in Intellectual Disabilities, 23, 75–84. https://doi.org/10.1111/j.1468-3148.2009.00548.x
Glover, G., Williams, R., Branford, D., Avery, R., Chauhan, U., Hoghton, M., & Bernard, S. (2015). Prescribing of psychotropic drugs to people with learning disabilities and/or autism by general practitioners in England. Public Health England.
Gore, N. J., Sapiets, S. J., Denne, L. D., Hastings, R. P., Toogood, S., MacDonald, A., Baker, P., Allen, D., Apanasionok, M. M., Austin, D., Bowring, D. L., Bradshaw, J., Corbett, A., Cooper, V., Deveau, R., Hughes, J. C., Jones, E., Lynch, M., McGill, P., et al. (2022). Positive behavioural support in the UK: A state of the nation report. International Journal of Positive Behavioural Support, 12(1), 4–39.
Gupta, S., Cahill, J. D., & Miller, R. (2018). Deprescribing antipsychotics: A guide for clinicians. British Journal of Psychiatry Advances, 24, 295–302. https://doi.org/10.1192/bja.2018.2
Hall, S., & Deb, S. (2008). A qualitative study on the knowledge and views that people with learning disabilities and their carers have of psychotropic medication prescribed for behaviour problems. Advances in Mental Health and Learning Disability, 2(1), 29–37.
Hassiotis, A., Kimona, K., Moncrieff, J., & Deb, S. (2016). A stakeholder consultation about future research of psychotropic medication use and behaviour support for adults with intellectual disabilities who present with behaviours that challenge: Feasibility of future research. NOCLOR https://www.ucl.ac.uk/psychiatry/sites/psychiatry/files/stakeholder-consultation-document.pdf
Jobski, K., Höfer, J., Hoffmann, F., & Bachmann, C. (2017). Use of psychotropic drugs in patients with autism spectrum disorders: A systematic review. Acta Psychiatrica Scandinavica, 135(1), 8–28. https://doi.org/10.1111/acps.12644
Knox, M. (2000). Family control: The views of families who have a child with an intellectual disability. Journal of Applied Research in Intellectual Disabilities., 13, 17–28. https://doi.org/10.1046/j.1468-3148.2000.00001.x
Luiselli, J. K. (2021). Applied behavior analysis treatment of violence and aggression in persons with neurodevelopmental disabilities. Springer.
Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121, e441–e448.
Murray, M. L., Hsia, Y., Glaser, K., Simonoff, E., Murphy, D. G., Asherson, P. J., Eklund, H., & Wong, I. C. (2014). Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology, 231, 1011–1021.
National Disabilities Insurance Scheme (NDIS) Quality and Safeguards Commission. (2020). Regulated restrictive practices guide. NDIS Quality and Safeguards Commission https://www.ndiscommission.gov.au/sites/default/files/2022-02/regulated-restrictive-practice-guide-rrp-20200.pdf (retrieved 15th September 2023)
National Institute for Health and Care Excellence (NICE). (2015). Challenging behaviour and learning disabilities: Prevention and interventions for people with learning disabilities whose behaviour challenges. In NICE Guideline 11 Methods evidence and recommendations.
Oliver-Africano, P. C., Dickens, S., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., Knapp, M., Hare, M., Meade, M., Reece, B., Bhaumik, S., Harley, D., Paichaud, J., Regan, A., Thomas, D. A., Keratela, S., Rao, B., Dzendrowskyj, T., Lenôtre, L., et al. (2010). Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. Journal of Intellectual Disability Research, 54, 17–25. https://doi.org/10.1111/j.1365-2788.2009.01195.x
Olson, D. A., Ingram, W., & Mann, J. R. (2002). Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation. Journal of Clinical Psychopharmacology, 22(5), 529–530.
Planès, S., Villier, C., & Mallaret, M. (2016). The nocebo effect of drugs. Pharmacology Research & Perspective, 4, e00208.
Ramerman, L., Hoekstra, P. J., & de Kuijper, G. (2018). Health-related quality of life in people with intellectual disability who use long-term antipsychotic drugs for challenging behaviour. Research in Developmental Disabilities, 75, 49–58.
Ratti, V., Hassiotis, A., Crabtree, J., Deb, S., Gallagher, P., & Unwin, G. (2016). The effectiveness of person-centred p
留言 (0)